<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>achieve</title>

    <!-- bootstrap css -->
    <link rel="stylesheet" href="asset/css/bootstrap.min.css" />
    <!-- owl-carousel  -->
    <link rel="stylesheet" href="asset/css/owl.carousel.min.css" />
    <!-- main CSS -->
    <link rel="stylesheet" href="asset/css/main.css" />
</head>

<body>
    <!-- ========================= -->
    <!-- header section  -->
    <!-- ========================= -->
    <div class="header-top-cnt blue">
        <p>THIS SITE IS FOR UK HEALTHCARE PROFESSIONALS ONLY</p>
    </div>
    <header class="header">
        <nav class="navbar navbar-expand-lg navbar-light p-0">
            <div class="collapse navbar-collapse" id="navbarSupportedContent">
                <ul class="navbar-nav align-items-center me-auto">
                    <li class="nav-item">
                        <a href="home.html" class="header-link">
                            <img src="asset/image/Home-icon.png" alt="" />
                            HOME</a>
                    </li>
                    <li class="nav-item active">
                        <a href="patient_experience.html" class="header-link">
                            <img src="asset/image/Patient-icon.png" alt="" />
                            patient experience</a>
                    </li>
                    <li class="nav-item">
                        <a href="about_brintellix.html" class="header-link">
                            <img src="asset/image/AB_ico.png" alt="" />
                            ABOUT BRINTELLIX</a>
                    </li>
                    <li >
                        <a href="#ref" class="header-link ref">
                            <img src="asset/image/AE_icon.png" alt="" />
                            report an adverse Event</a>
                    </li>
                    <li class="nav-item">
                        <a href="asset/pdf/Brintellix Prescribing Information (April 2022) for digital use v5.pdf" target="_blank" class="header-link">
                            <img src="asset/image/PI_icon.png" alt="" />
                            prescribing information</a>
                    </li>
                </ul>
            </div>
            
            <a class="navbar-brand logo" href="home.html"><img src="asset/image/logo.png" alt="" /></a>
            <button id="nav-burger">
                <span></span>
                <span></span>
                <span></span>
                <span></span>
            </button>
        </nav>
        <hr class="divider" />
    </header>
    <!-- ========================= -->
    <!-- feel section  -->
    <!-- ========================= -->
    <section class="feel-sec ">
        <div class="li li-two" data-parallax="scroll" data-image-src="asset/image/feel-sec-bg2.png" data-z-index="1">
            <div class="nav-btn">
                <a href="feel.html" class="arrow-btn"><img src="asset/image/left-arrow.png" alt=""></a>
                <a href="forward.html" class="arrow-btn arrow-btn-right"><img src="asset/image/right-arrow.png" alt=""></a>
            </div>
            <div class="container">
                <div class="banner-wraper">
                    <p class="major">
                        Brintellix (vortioxetine) is indicated for the treatment of major
                        depressive episodes in adults.¹<br />
                        Prescribing information can be accessed via the tab at the top of
                        this page.
                    </p>
                    <div class="feel-sec-cnt">
                        <h2>I want to ACHIEVE</h2>
                        <figure class="feel-image">
                            <img src="asset/image/feel-sec-img2.png" alt="" />
                        </figure>
                        <h3>
                            How might Brintellix help adults like Rebecca diagnosed with MDD
                            who keep needing to take time off work?
                        </h3>
                    </div>
                </div>
            </div>
            <ul class="dots-body">
                <li ></li>
                <li class="active"></li>
                <li></li>
                <li></li>
                <li></li>
            </ul>
            <span class="used">Fictional patients used for illustrative purposes.</span>
        </div>
        
    </section>
    <!-- ========================= -->
    <!-- feelings section  -->
    <!-- ========================= -->
    <section class="feelings cmn-banner">
        <figure class="feelings-bg">
            <img class="feelings-bg1" src="asset/image/feelings-bg2.png" alt="" />
            <img class="display-none" src="asset/image/orange-sm-bg.png" alt="">
        </figure>
        <div class="container">
            <div class="row flex-md-column-reverse flex-sm-column-reverse flex-column-reverse flex-lg-row">
                <div class="col-lg-6">
                    <div class="feelings-cnt-left">
                        <div class="feelings-top-cnt">
                            <h4>
                                As an assistant at a marketing company, Rebecca attends
                                several meetings every day and works to tight deadlines.
                            </h4>
                            <p>
                                She needs to stay alert to keep on top of her work, but with
                                her MDD, she struggles to maintain her energy levels and
                                concentration. There are even some days where she finds it
                                hard to get out of bed in the morning.
                            </p>
                        </div>
                        <div class="defined-cnt">
                            <h4>Depression absence:</h4>
                            <p>
                                Depression is one of the most prevalent health problems in the
                                workplace.² Mental health disorders, including stress,
                                depression, anxiety, and serious mental health conditions
                                accounted for 9.8% of all sickness absence in the UK during
                                2021.³
                            </p>
                        </div>
                    </div>
                </div>
                <div class="col-lg-6">
                    <div class="feelings-cnt-right">
                        <figure class="round-img">
                            <img src="asset/image/round-img2.png" alt="" />
                        </figure>
                        <h2>
                            Patients like Rebecca receiving Brintellix may see improvements
                            in their attendance at work.⁴
                        </h2>
                        <span class="depressive"><strong>MDD,</strong> major depressive disorder.  </span>
                    </div>
                </div>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- desing section  -->
    <!-- ========================= -->
    <section class="design">
        <div class="container2">
            <div class="row desing-row  ">
                <div class="design-left">
                    <h4>
                        Patients receiving Brintellix are more able to fully engage in
                        their jobs long-term⁴
                    </h4>
                    <p class="demi">
                        The AtWoRC study assessed whether improvements in cognitive
                        symptoms in Brintellix-treated patients correlated with increased
                        work productivity in a real-life setting vs. baseline:⁴
                    </p>
                    <ul class="both">
                        <li class="pe-3">
                            <span class="week ">Primary study endpoint was the partial correlation between
                                changes in PDQ-D-20 and WLQ productivity loss scores at Week
                                12*</span>
                        </li>
                        <li>
                            <span class="week">The percentage of patients reporting missed work days due to
                                depression was significantly reduced from baseline by 52 weeks
                                (secondary outcome)</span>
                        </li>
                    </ul>
                </div>
                <div class="design-right">
                    <div class="desing-right-cnt">
                        <span class="change">Proportion of patients with time off work due to depression in
                            the past 3 months (FAS, n=199)</span>
                        <div class="dougnut-chart-body">
                            <figure class="char-img1">
                                <img src="asset/image/chart-img5.png" alt="" />
                            </figure>
                        </div>
                        <div class="chart-btm-cnt">
                            <span class="adapted pb-2">Adapted from: Chokka P et al. 2019.⁴</span>
                        </div>
                    </div>
                </div>
            </div>
            <div class="rating">
                <p>
                    *Correlation was assessed by the partial correlation coefficient
                    adjusted for age, sex, baseline PDQ-D-20, baseline WLQ productivity
                    loss, disease duration, and disease severity.
                </p>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- desing-2 section  -->
    <!-- ========================= -->
    <section class="design">
        <div class="container2">
            <div
                class="row desing-row    flex-lg-row-reverse">
                <div class="design-left">
                    <h4 class="see-h4">
                        Patients receiving Brintellix see improvements from baseline in their productivity at work⁴
                    </h4>
                    <ul class="both">
                        <li>
                            <span class="week">Work productivity loss significantly reduced over the 52-week treatment
                                period vs. baseline (p 0.001)</span>
                        </li>
                        <li>
                            <span class="week">Mean (SD) change from baseline in WLQ productivity loss score was -8.9
                                (5.9) at 52 weeks</span>
                        </li>

                    </ul>
                    <button type="button" class="popup-btn study-btn" data-bs-toggle="modal"
                        data-bs-target="#study-modal2">
                        Study design
                    </button>
                </div>
                <div class="design-right">
                    <div class="desing-right-cnt">
                        <span class="change">Work productivity loss: mean WLQ score over 52 weeks (FAS, n=199)†</span>
                        <figure class="char-img1">
                            <img src="asset/image/chart-img7.png" alt="" />
                        </figure>
                        <div class="chart-btm-cnt">
                            <span class="adapted pb-2">Adapted from: Chokka P et al. 2019.⁴</span>
                            <span class="adapted">*p < 0.001. †Functioning and work productivity were assessed by WLQ
                                    productivity loss, the SDS, the WPAI questionnaire, and the WHODAS. Changes in WLQ
                                    productivity loss over 52 weeks of follow-up are shown; error bars indicate 95%
                                    confidence intervals. Statistically significant improvements (p 0.001, paired t
                                    test) versus baseline were found at Week 52. </span>
                        </div>
                    </div>
                </div>
            </div>
            <div class="rating">
                <p>
                    AtWoRC, Assessment in Work productivity and the Relationship with Cognitive symptoms; FAS, Full
                    Analysis Set; PDQ-D-20, 20-item Perceived Deficits Questionnaire – Depression; SD, Standard
                    deviation; SDS, Sheehan Disability Scale; WHODAS 2.0, 12-item World Health Organization Disability
                    Assessment Schedule 2.0; WLQ, Work Limitations Questionnaire; WPAI, Work Productivity and Activity
                    Impairment questionnaire.
                </p>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- desing2 section  -->
    <!-- ========================= -->
    <section class="design desing2">
        <div class="container2">
            <div
                class="row desing-row  ">
                <div class="design-left desing-left2">
                    <h4>
                        Brintellix has demonstrated improvements in patient-reported
                        functioning in real-world patients with MDD⁵
                    </h4>
                    <p class="pb-lg-4 pb-3">
                        In the real-world, 24-week observational, prospective cohort study
                        of Brintellix in a large, heterogeneous patient population with
                        MDD (n=737):⁵
                    </p>
                    <ul class="both">
                        <li>
                            <span class="week">Clinically meaningful, <strong>sustained improvement in patient
                                functioning</strong> was seen over <strong>24 weeks of Brintellix treatment</strong> ( p < 0.0001)
                            </span>
                        </li>
                        <li>
                            <span class="week"><strong>Significant reductions in all SDS domain scores were observed</strong>
                                at 12 and 24 weeks vs. baseline (p 0.0001 for both)</span>
                        </li>
                        <li class="severity">
                            <h4>Depression Severity</h4>
                        </li>
                        <li>
                            <span class="week">In the subgroup of patients with moderately severe to severe
                                depression at baseline (PHQ-9 score ≥15), significant and
                                sustained improvements in functioning and all secondary
                                endpoints were seen over the 24 weeks of Brintellix
                                treatment⁵</span>
                        </li>
                        <li class="severity">
                            <span class="mean">Mean reductions in absenteeism (work days lost) and presenteeism (work
                                days underproductive) after 24 weeks of Brintellix treatment were 1.1 and 2.2 days/week,
                                respectively <sup>5</sup></span>
                        </li>
                    </ul>
                    <button type="button" class="popup-btn study-btn" data-bs-toggle="modal"
                        data-bs-target="#study-modal3">
                        Study design
                    </button>
                </div>
                <div class="design-right">
                    <div class="desing-right-cnt">
                        <span class="change">SDS total and domain scores at baseline and after 12 and 24 weeks (FAS,
                            n=737)
                            (adjusted LS mean (95% CI) score)</span>
                        <figure class="char-img1">
                            <img src="asset/image/chart-img6.png" alt="" />
                        </figure>
                        <div class="chart-btm-cnt">
                            <span class="adapted pb-2">Adapted from: Mattingly et al. 2022.⁵</span>
                        </div>
                    </div>
                </div>
            </div>
            <div class="rating">
                <p>
                    CI, Confidence interval; FAS, Full analysis set; LS, Least squares; MDD, major depressive disorder
                    SE, standard error; SDS, Sheehan Disability Scale.
                </p>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- warnings section  -->
    <!-- ========================= -->
    <section class="warnings">
        <div class="container">
            <div class="warnings-warp">
                <p>
                    For further information about Brintellix, including Tolerability,
                    Special Warnings and Precautions and Contraindications, please visit
                    the About Brintellix Section
                </p>
                <a href="about_brintellix.html" class="btn-more about-btn">about brintellix</a>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- deserve section  -->
    <!-- ========================= -->
    <section class="deserve">
        <div class="container">
            <div class="deserve-wrap">
                <h3>Explore more in the sections below:</h3>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- feel section  -->
    <!-- ========================= -->
    <section class="feel">
        <ul class="feel-body">
            <li class="light-orange">
                <h4>
                    I want to <br />
                    FEEL
                </h4>
                <figure class="feel-img">
                    <img src="asset/image/feel-img1.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in anhedonia and emotional blunting</p>
                </div>
                <a href="feel.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-2">
                <h4>
                    I want to
                    <br />
                    ACHIEVE
                </h4>
                <figure class="feel-img">
                    <img class="feel-img2" src="asset/image/feel-img2.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in work productivity, presenteeism and functioning</p>
                </div>
                <a href="achieve.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-3">
                <h4>
                    I want to <br />
                    MOVE FORWARD
                </h4>
                <figure class="feel-img">
                    <img class="feel-img3" src="asset/image/feel-img3.png" alt="" />
                </figure>
                <div class="function">
                    <p>
                        Brintellix in patients with MDD together with anxiety and a
                        history of trauma
                    </p>
                </div>
                <a href="forward.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-4">
                <h4>
                    I want to <br />
                    FOCUS
                </h4>
                <figure class="feel-img">
                    <img src="asset/image/feel-img4.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in cognition</p>
                </div>
                <a href="focus.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-5">
                <h4>
                    I want to <br />
                    MAINTAIN
                </h4>
                <figure class="feel-img">
                    <img src="asset/image/feel-img5.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix in remission and relapse</p>
                </div>
                <a href="maintain.html" class="btn-more btn-more-2">MORE</a>
            </li>
            <li class="light-orange-6">
                <h4>
                    I want to <br />
                    LIVE
                </h4>
                <figure class="feel-img">
                    <img class="feel-img3" src="asset/image/feel-img6.png" alt="" />
                </figure>
                <div class="function">
                    <p>Brintellix and sexual functioning</p>
                </div>
                <a href="live.html" class="btn-more btn-more-2">MORE</a>
            </li>
        </ul>
    </section>
    <!-- ========================= -->
    <!-- reference   section  -->
    <!-- ========================= -->
    <section class="reference" id="ref">
        <div class="container">
            <div class="reference-wrap">
                <div class="adverse-blk">
                    <span class="events">Adverse events should be reported.
                    </span>
                    <p>Reporting forms and information can be found at <a href="#"
                            class="yellowcard">www.mhra.gov.uk/yellowcard</a> Adverse events should
                        also be reported to Lundbeck Limited, Medical Information, on: <a class="mobile-number" href="tel:01908 638972">01908 638972</a> or Email:
                        <a href="mailto:SafetyLuUnitedKingdom@lundbeck.com" class="yellowcard"> SafetyLuUnitedKingdom@lundbeck.com</a>
                        
                    </p>
                    
                </div>
                <div class="reference-cnt">
                    <span class="ref-head demi">References</span>
                    <ul class="reference-list">
                        <li>
                            <span>Lundbeck. Brintellix. Summary of Product Characteristics GB and NI.</span>
                        </li>
                        <li>
                            <span>Sanderson K, Andrews G. Can J Psychiatry. 2006;51:63–75.
                            </span>
                        </li>
                        <li>
                            <span>Office for National Statistics, Sickness absence in the UK labour market: 2021. Available https://www.ons.gov.uk/ employmentandlabourmarket/peopleinwork/labourproductivity/articles/sicknessabsenceinthelabourmarket/2021. [Last accessed June 2023].  
                            </span>
                        </li>
                        <li>
                            <span>Chokka P et al. CNS Spectr 2019;24:616–627. 
                            </span>
                        </li>
                        <li>
                            <span>Mattingly GW et al. Front Psychiatry 2022;13:824831. 
                            </span>
                        </li>
                    </ul>
                    <span class="ref-head">UK-BRIN-1281 | June 2023</span>
                </div>
            </div>
        </div>
    </section>
    <!-- ========================= -->
    <!-- footer   section  -->
    <!-- ========================= -->
    <footer>
        <hr class="footer-divider" />
        <div class="container">
            <div class="row">
                <div class="footer-log d-flex">
                    <a href="#" class="footer-logo"><img src="asset/image/footer-logo.png" alt="" /></a>
                </div>
                <div class="location">
                    <p>
                        <strong class="demi">Lundbeck Limited</strong><br />
                        Iveco House, Station Road <br />
                        Watford, Hertfordshire <br />
                        WD17 1ET <br />
                        United Kingdom
                    </p>
                    <span class="ref-head">UK-BRIN-1360 | June 2023</span>
                </div>
                <div class="contact">
                    <span class="ref-head demi">Contact us </span>
                    <a class="mail-link" href="tel:+44 1908 649 966">+44 1908 649 966</a>
                    <a href="mailto:united_kingdom@lundbeck.com" class="mail-link">united_kingdom@lundbeck.com</a>
                </div>
                <div class="footer-link-cnt">
                    <span class="ref-head demi">Links</span>
                    <ul class="footer-links">
                        <li><a href="contact.html" class="footer-link">Contact us </a></li>
                        <li><a href="terms_of_use.html" class="footer-link">Terms of Use</a></li>
                        <li>
                            <a href="#" class="footer-link">Report an Adverse Event</a>
                        </li>
                        <li>
                            <a href="privacy.html" class="footer-link">Website Privacy Policy</a>
                        </li>
                        <li><a href="cookie_policy.html" class="footer-link">Cookies settings</a></li>
                        <li>
                            <a href="asset/pdf/Brintellix Prescribing Information (April 2022) for digital use v5.pdf" target="_blank" class="footer-link">Prescribing information </a>
                        </li>
                    </ul>
                </div>
            </div>
        </div>
    </footer>

    <!----------------------- JQUERY ----------------->
    <script src="asset/js/jquery-min.js"></script>

    <!-- BOOTSTRAP JS -->
    <script src="asset/js/bootstrap.bundle.min.js"></script>
    <!----------------------- OWL CAROUSEL ----------------->
    <script src="asset/js/owl.carousel.min.js"></script>
    <!-- script js -->
    <script src="asset/js/script.js"></script>
     <!-- parallax  -->
     <script src="asset/js/parallax.js"></script>
    <!--study 1  Modal -->
    <div class="modal fade" id="study-modal2" tabindex="-1" aria-labelledby="exampleModalLabel" aria-hidden="true">
        <div class="modal-dialog modal-dialog-centered  modal-dialog2">
            <div class="modal-content">
                <div class="modal-header">
                    <button type="button" class="close-btn" data-bs-dismiss="modal" aria-label="Close">
                        <img src="asset/image/close.png" alt="" />
                    </button>
                </div>
                <div class="study-popup-blk">
                    <span class="cao">Chokka P et al. 2019 <sup>1,2</sup></span>
                    <h3>
                        Non-randomised, interventional, open-label, flexible-dose, single-cohort study recruited
                        randomised patients receiving Brintellix at 26 sites in Canada
                    </h3>
                    <span class="mean-20 pb-2">52-week treatment period</span>
                    <div class="rotate-sm">
                        <figure><img src="asset/image/rotate.png" alt=""></figure>
                        <span class="font-size-16"> Rotate your device for a larger view of the study design</span>
                    </div>
                    <figure class="vocational"><img src="asset/image/vocational-img1.png" alt=""></figure>
                    <div class="analysis-cnt">
                        <p> <strong>Primary efficacy analysis: </strong> to describe the correlation between change in patient-reported
                            cognitive symptoms (assessed using the PDQ-D-20) and work productivity loss (assessed using
                            the WLQ) from baseline to Week 12. Baseline depression severity was controlled for in the
                            primary analysis.
                        </p>
                        <p><strong>Secondary efficacy analysis: </strong> changes in disease and symptom severity, cognitive symptoms and
                            performance, work productivity, functioning, and symptoms of anxiety (QIDS-SR, CGI-S, CGl-I,
                            PDQ-D-20, DSST, WLQ productivity loss, WPAI overall impairment, SDS, WHODAS and GAD-7,
                            respectively) from baseline to Weeks 12 and 52. Treatment response rates and remission rates
                            were also calculated at Weeks 12 and 52. Safety was evaluated at Week 52 (study completion)
                            and at Week 56.
                        </p>
                        <p><strong>Tolerability:</strong> The most common treatment-emergent adverse events were nausea (29.2%), headache
                            (11.9%), insomnia (9.1%), nasopharyngitis (6.8%), anxiety (6.4%), and dizziness (5.9%).</p>
                    </div>
                    <div class="licensed">
                        <span>*Patients received 10mg of Brintellix in the first 12 weeks of the study. From Week 12 to
                            Week 52 dosing was flexible, 10-20mg.
                        </span>
                        <span>The licensed starting dose of Brintellix for patients aged 65
                            or over is 5 mg/day.
                        </span>
                        <p>
                            CGI-I, Clinical Global Impression - Improvement; CGI-S, Clinical Global Impression -
                            Severity; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; DSST,
                            Digit Symbol Substitution Test; GAD-7, 7-item Generalised Anxiety Disorder Scale; MDD, major
                            depressive disorder; PDQ-D-20, 20-items Perceived Deficits Questionnaire - Depression;
                            QIDS-SR, Quick Inventory of Depressive Symptomatology - Self Report; SDS, Sheehan Disability
                            Scale; WHODAS, 12-item World Health Organization Disability Assessment Schedule 2.0; WLQ,
                            Work Limitations Questionnaire; WPAI, Work Productivity and Activity Impairment.
                        </p>
                        <p>
                            <strong>References:</strong> 1. Chokka P, et al. Long-term functioning outcomes are predicted by cognitive
                            symptoms in working patients with major depressive disorder treated with vortioxetine:
                            results from the AtWoRC study. CNS Spectrums. 2019 Dec;24(6):616-627. 2. Chokka P et al.
                            Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC):
                            primary analysis from a Canadian open-label study of vortioxetine in patients with major
                            depressive disorder (MDD). CNS Spectrums 2019 Jun;24(3):338-347.
                        </p>
                    </div>
                    <div class="inhibitor justify-content-end w-100">
                        <span>UK-BRIN-1281 | June 2023</span>
                    </div>
                </div>
            </div>
        </div>
    </div>
    <!--study 2  Modal -->
    <div class="modal fade" id="study-modal3" tabindex="-1" aria-labelledby="exampleModalLabel" aria-hidden="true">
        <div class="modal-dialog modal-dialog-centered  modal-dialog2">
            <div class="modal-content">
                <div class="modal-header">
                    <button type="button" class="close-btn" data-bs-dismiss="modal" aria-label="Close">
                        <img src="asset/image/close.png" alt="" />
                    </button>
                </div>
                <div class="study-popup-blk">
                    <span class="cao">Mattingly GW et al. 2022¹</span>
                    <h3>
                        A 24-week, observational, prospective cohort study in outpatients with MDD assessing the
                        effectiveness of Brintellix in patients with MDD treated in routine clinical care settings.
                    </h3>
                    <span class="font-size-16-br"><strong>Study objective:</strong> To assess the effect of Brintellix on self-reported
                        patient
                        functioning after 6 months of treatment using the SDS – focusing on the patient’s own assessment
                        of their functioning in daily life and the improvement experienced during treatment using a
                        validated and easy-to-use scale.</span>
                        <div class="rotate-sm">
                            <figure><img src="asset/image/rotate.png" alt=""></figure>
                            <span class="font-size-16"> Rotate your device for a larger view of the study design</span>
                        </div>
                    <figure class="vocational"><img src="asset/image/vocational-img2.png" alt=""></figure>
                    <div class="analysis-cnt">
                        <p><strong>Primary endpoint:</strong> Mean change from baseline in SDS total score assessed at weeks 12 and 24.
                        </p>
                        <p><strong>Secondary endpoints:</strong> Secondary endpoints included mean change from baseline at weeks 12 and
                            24 for SDS domain scores <br>
                            and PHQ-9, CGI-S, CGI-I, PDQ-D-5, DSST, EQ-5D-5L, and ASEX scores.

                        </p>
                        <p><strong>Tolerability results:</strong> The most commonly reported adverse events (AEs) were nausea, headache,
                            pruritus, and anxiety. No new <br>
                            safety issues were reported.</p>
                    </div>
                    <div class="licensed">

                        <span>The licensed starting dose of Brintellix for patients aged 65
                            or over is 5 mg/day.
                        </span>
                        <span>*Brintellix 15 mg is not available for use in the UK.</span>
                        <p>
                            ASEX, Arizona Sexual Experience Scale; CGI-I, Clinical Global Impression-Improvement; CGI-S,
                            Clinical Global Impression-Severity; DSST, Digit Symbol Substitution Test; EQ-5D-5L, EuroQoL
                            5 dimensions 5 levels utility index; MDD, Major Depressive Disorder; MDE, major depressive
                            episode; PDQ-D-5, 5-item Perceived Deficits Questionnaire-Depression; PHQ-9, Patient Health
                            Questionnaire; SDS, Sheehan Disability Scale.
                        </p>
                        <p>
                            <strong>Reference:</strong> 1. Mattingly GW et al. Front Psychiatry 2022;13:824831.
                        </p>
                    </div>
                    <div class="inhibitor justify-content-end w-100">
                        <span>UK-BRIN-1281 | June 2023</span>
                    </div>
                </div>
            </div>
        </div>
    </div>
</body>

</html>